LBA19 SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01)

作者：Erqun Song, Herui Yao, H. Li, Yuzhen Yin, Qiang Zhang, Song Wang, Quchang Ouyang, Tao Sun, Xian Wang, Wen Xie, B. Wang, Wei Li, Min Yan, Chang‐An Geng, Yue Peng, Yue Yang, Feng Dong, Yue Zhang, Lin Cheng, Xiaodong Zhu · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.029 · 被引用次数：7 · 研究领域：HER2/EGFR in Cancer Research、Cancer Treatment and Pharmacology、Advanced Breast Cancer Therapies